| 前收市價 | 1.7000 |
| 開市 | 2.5500 |
| 買盤 | 0.0000 |
| 賣出價 | 0.0000 |
| 拍板 | 40.50 |
| 到期日 | 2024-07-19 |
| 今日波幅 | 2.5500 - 2.5500 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
BloombergBird Flu Shot Hopes Dim as Tracing Woes Undercut Covid Lessons
(Bloomberg) -- US scientists haven’t gotten a handle on how to effectively track bird flu, three months after a Texas dairy worker was diagnosed with the virus. That’s impeding the ability to create a vaccine to protect against the spread among people.Most Read from BloombergDemocrats Weigh Mid-July Vote to Formally Tap Biden as NomineeTrump Immunity Ruling Means Any Trial Before Election UnlikelyBlackRock Buys Preqin for $3.2 Billion in Private Data PushTrump as President or Private Citizen: Wh
Insider MonkeyGSK plc (GSK): Did This Healthcare Stock Show a Strong Performance in Q1?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy Under $50. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other healthcare stocks under $50. If interested, you can also read our recent article on the 10 Best Healthcare Stocks To Buy […]
BenzingaCDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
On Wednesday, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine use of Respiratory Syncytial Virus (RSV) vaccines in all adults aged 75 and above. The panel also recommended RSV immunization for adults aged 60-74 years who are at increased risk for severe RSV disease, meaning they have certain chronic medical conditions. The recommendation is for adults who did not get an RSV vaccine last year. The RSV v
